Target intelligence / Profile preview

Mitochondrial ornithine transporter 2 (SLC25A2)

Target
SLC25A2
Molecular classification
Transporter, Mitochondrial carrier, Solute carrier family
01

Overview

Mitochondrial ornithine transporter 2 (SLC25A2) is a member of the solute carrier family 25, localized in the inner mitochondrial membrane, where it mediates the transport of ornithine and related basic amino acids (lysine, arginine, citrulline, histidine) between the cytoplasm and mitochondrial matrix. It functions primarily as an exchanger and is essential for the proper functioning of the urea cycle, facilitating the fixation of ammonia for detoxification. SLC25A2 is widely expressed, most strongly in the liver, kidney, pancreas, and several other tissues. It has a broader substrate specificity than its paralog SLC25A15 (ORC1), and its activity can partially compensate for ORC1 deficiency in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (HHH), though SLC25A2 itself has not been directly linked to human disease as the sole causative gene. The transporter is inhibited by the polyamine spermine. No approved therapeutics specifically target SLC25A2; its biologically critical function places it among potential therapeutic targets related to metabolic or mitochondrial disease, though clinical targeting is currently limited.

Other names
ORC2ORNT2Solute carrier family 25 member 2Mitochondrial ornithine transporter 2solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 2
02

Mechanism of action

Exchange (counter-transport) of ornithine, citrulline, and basic amino acids across the mitochondrial inner membrane

03

Biological functions

Amino acid transport across the inner mitochondrial membraneOrnithine/citrulline exchange in the urea cycle
04

Disease associations

Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome (compensatory/secondary role)Possibly metabolic disorders involving urea cycle dysfunction
05

Safety considerations

Loss-of-function mutations in related protein SLC25A15 cause metabolic disease; genetic variations in SLC25A2 may alter transporter activity but are not primary drivers of disease
06

Interacting drugs

Spermine (inhibitor)
07

Biomarkers

None known for patient selection or efficacy monitoring

Beyond the preview

Go deeper on Mitochondrial ornithine transporter 2 (SLC25A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial ornithine transporter 2 (SLC25A2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call